Additionally we observed multiple genes in RAS pathway to be differentially methylated across the cytogenetic risk groups: RASSF5 and RASGRF1 in inv(16) cases; RASA3 in t(8;21) cases; RASSF2 in t(9;11); RASSF4 in other MLL-(11q23); DIRAS1 in miscellaneous abnormalities and normal cytogenetics AML, highlighting the significance of these pathways and genes impacted in different cytogenetic subgroups. This evidence concerns the gene KMT2A and acute myeloid leukemia.